Cadrenal Therapeutics (CVKD) Competitors $18.46 -0.25 (-1.34%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$18.38 -0.09 (-0.46%) As of 03/28/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. TIL, PRQR, MGNX, ALEC, OGI, ZNTL, SAVA, VXRT, ENTA, and GNLXShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Instil Bio (TIL), ProQR Therapeutics (PRQR), MacroGenics (MGNX), Alector (ALEC), Organigram (OGI), Zentalis Pharmaceuticals (ZNTL), Cassava Sciences (SAVA), Vaxart (VXRT), Enanta Pharmaceuticals (ENTA), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Instil Bio ProQR Therapeutics MacroGenics Alector Organigram Zentalis Pharmaceuticals Cassava Sciences Vaxart Enanta Pharmaceuticals Genelux Cadrenal Therapeutics (NASDAQ:CVKD) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Do insiders & institutionals believe in CVKD or TIL? 7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 48.6% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 46.5% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate CVKD or TIL? Cadrenal Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 73.35%. Instil Bio has a consensus price target of $114.00, suggesting a potential upside of 530.53%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, CVKD or TIL? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$8.67-2.13Instil BioN/AN/A-$156.09M-$11.39-1.59 Is CVKD or TIL more profitable? Instil Bio's return on equity of -37.44% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -142.95% -118.40% Instil Bio N/A -37.44%-25.08% Does the MarketBeat Community favor CVKD or TIL? Instil Bio received 96 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 50.50% of users gave Instil Bio an outperform vote. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesInstil BioOutperform Votes10250.50% Underperform Votes10049.50% Which has more risk & volatility, CVKD or TIL? Cadrenal Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Does the media refer more to CVKD or TIL? In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Cadrenal Therapeutics' score of 0.44 indicating that Instil Bio is being referred to more favorably in the news media. Company Overall Sentiment Cadrenal Therapeutics Neutral Instil Bio Very Positive SummaryInstil Bio beats Cadrenal Therapeutics on 10 of the 15 factors compared between the two stocks. Remove Ads Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.71M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-2.767.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book2.086.396.894.23Net Income-$8.36M$142.12M$3.20B$247.15M7 Day Performance-4.70%-5.18%-3.02%-2.17%1 Month Performance-2.84%-7.49%1.63%-5.68%1 Year PerformanceN/A-8.78%9.74%-0.67% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics2.5761 of 5 stars$18.46-1.3%$32.00+73.3%N/A$34.71MN/A-2.764Short Interest ↑TILInstil Bio3.1844 of 5 stars$21.63+8.8%$114.00+427.0%+67.4%$141.16MN/A-1.87410PRQRProQR Therapeutics1.9789 of 5 stars$1.70+0.6%$9.50+458.8%-38.3%$138.86M$18.91M-5.31180Analyst RevisionPositive NewsGap UpMGNXMacroGenics3.8781 of 5 stars$2.18-1.8%$7.63+249.8%-91.4%$136.82M$139.77M-1.38430Analyst ForecastAnalyst RevisionALECAlector3.8069 of 5 stars$1.38-4.8%$3.50+153.6%-78.6%$136.74M$100.56M-0.81270OGIOrganigram0.6988 of 5 stars$1.07+3.9%N/A-52.1%$135.05M$166.12M-2.82860Positive NewsZNTLZentalis Pharmaceuticals1.938 of 5 stars$1.89+6.8%$8.24+336.2%-88.5%$134.69M$40.56M-0.76160Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSAVACassava Sciences3.8753 of 5 stars$2.78-0.4%$111.50+3,910.8%-91.9%$134.30MN/A-2.0130Analyst ForecastShort Interest ↓VXRTVaxart2.2013 of 5 stars$0.58+6.7%$4.00+595.2%-67.6%$130.89M$20.14M-1.40120Analyst ForecastAnalyst RevisionNews CoverageENTAEnanta Pharmaceuticals4.0007 of 5 stars$6.10-8.3%$17.25+182.8%-67.3%$130.13M$66.59M-1.23160GNLXGenelux1.4628 of 5 stars$3.73+9.7%$18.25+389.3%-52.1%$128.83M$8,000.00-3.9310Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies TIL Competitors PRQR Competitors MGNX Competitors ALEC Competitors OGI Competitors ZNTL Competitors SAVA Competitors VXRT Competitors ENTA Competitors GNLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
